ACRV

1.74

0.85% -0.03

Handel nachbörslich: 1.74

Acrivon Therapeutics Inc (ACRV)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$1.77

Offen:

$1.73

24-Stunden-Volumen:

242.76K

Relative Volume:

0.20

Marktkapitalisierung:

$54.73M

Einnahmen:

Nettoeinkommen (Verlust:

$-69.00M

KGV:

-0.6259

EPS:

-2.78

Netto-Cashflow:

$-55.26M

1W Leistung:

-8.12%

1M Leistung:

+15.46%

6M Leistung:

+17.00%

1J Leistung:

-75.83%

1-Tages-Spanne:

$1.685

$1.80

1-Wochen-Bereich:

$1.685

$2.02

52-Wochen-Spanne:

$1.05

$8.74

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Firmenname

Acrivon Therapeutics Inc

Sektor

Healthcare (1146)

Branche

Biotechnology (639)

Telefon

617-207-8979

Adresse

480 ARSENAL WAY, SUITE 100, WATERTOWN

Mitarbeiter

Twitter

Nächster Verdiensttermin

2025-08-08

Neueste SEC-Einreichungen

ACRV's Discussions on Twitter

Vergleichen Sie ACRV mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ACRV Acrivon Therapeutics Inc	1.74	55.68M	0	-69.00M	-55.26M	-2.78
VRTX Vertex Pharmaceuticals Inc	412.22	104.45B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	469.36	60.95B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	572.60	59.11B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	812.95	49.23B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.94	35.92B	4.56B	-176.77M	225.30M	-1.7177

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-05	Fortgesetzt	Piper Sandler	Overweight
2025-01-31	Eingeleitet	KeyBanc Capital Markets	Overweight
2024-09-16	Hochstufung	Ladenburg Thalmann	Neutral → Buy
2024-04-29	Herabstufung	Ladenburg Thalmann	Buy → Neutral
2024-03-01	Eingeleitet	JMP Securities	Mkt Outperform
2023-12-15	Fortgesetzt	Jefferies	Buy
2023-10-05	Eingeleitet	Maxim Group	Buy
2023-06-02	Eingeleitet	Oppenheimer	Outperform
2023-05-08	Eingeleitet	BMO Capital Markets	Outperform
2023-04-27	Eingeleitet	Ladenburg Thalmann	Buy
2023-04-20	Eingeleitet	H.C. Wainwright	Buy
2022-12-12	Eingeleitet	Cowen	Outperform
2022-12-12	Eingeleitet	Jefferies	Buy
2022-12-12	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Acrivon Therapeutics Inc Aktie (ACRV) Neueste Nachrichten

06:51 AM

Is Acrivon Therapeutics Inc. still worth holding after the dip2025 Breakouts & Breakdowns & Smart Allocation Stock Tips - newser.com

06:51 AM

04:55 AM

Will Acrivon Therapeutics Inc. stock split attract more investorsQuarterly Growth Report & Technical Pattern Recognition Alerts - newser.com

04:55 AM

04:53 AM

Is Acrivon Therapeutics Inc. building a consolidation base2025 Investor Takeaways & Weekly High Return Stock Opportunities - newser.com

04:53 AM

03:10 AM

Can Acrivon Therapeutics Inc. hit a new high this monthPortfolio Risk Report & Free Long-Term Investment Growth Plans - newser.com

03:10 AM

02:42 AM

Is Acrivon Therapeutics Inc. stock supported by strong cash flowsJuly 2025 Outlook & Daily Chart Pattern Signals - newser.com

02:42 AM

Oct 13, 2025

Is Acrivon Therapeutics Inc. stock a contrarian buyJuly 2025 Retail & Verified Chart Pattern Trade Signals - newser.com

Oct 13, 2025

Will Acrivon Therapeutics Inc. stock benefit from green energy trends2025 Market Trends & High Accuracy Swing Entry Alerts - newser.com

Oct 13, 2025

Custom strategy builders for tracking Acrivon Therapeutics Inc.Earnings Growth Report & Precise Swing Trade Entry Alerts - newser.com

Oct 13, 2025

Oct 11, 2025

News impact scoring models applied to Acrivon Therapeutics Inc.July 2025 Trade Ideas & Fast Exit and Entry Strategy Plans - newser.com

Oct 11, 2025

Oct 09, 2025

How Acrivon Therapeutics Inc. stock valuations compare to rivalsMarket Performance Recap & Daily Technical Stock Forecast Reports - newser.com

Oct 09, 2025

What Fibonacci levels say about Acrivon Therapeutics Inc. reboundPortfolio Value Report & Fast Moving Stock Trade Plans - newser.com

Oct 09, 2025

Is Acrivon Therapeutics Inc. stock positioned well for digital economyPortfolio Gains Summary & Safe Entry Momentum Stock Tips - newser.com

Oct 09, 2025

Oct 08, 2025

Acrivon Therapeutics (NASDAQ:ACRV) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat

Oct 08, 2025

Oct 06, 2025

Sector ETF performance correlation with Acrivon Therapeutics Inc.July 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com

Oct 06, 2025

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates - 富途牛牛

Oct 06, 2025

Oct 05, 2025

Risk vs reward if holding onto Acrivon Therapeutics Inc.July 2025 Market Mood & Safe Entry Trade Reports - newser.com

Oct 05, 2025

Will Acrivon Therapeutics Inc. stock benefit from sector rotationInflation Watch & Fast Entry Momentum Alerts - newser.com

Oct 05, 2025

What to expect from Acrivon Therapeutics Inc. in the next 30 daysJuly 2025 Highlights & High Accuracy Investment Entry Signals - newser.com

Oct 05, 2025

Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Rises By 127.8% - Defense World

Oct 05, 2025

Oct 04, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 127.8% in September - MarketBeat

Oct 04, 2025

Oct 02, 2025

Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap - simplywall.st

Oct 02, 2025

Oct 01, 2025

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Oct 01, 2025

225,000 Stock Options: Biotech Acrivon Therapeutics Awards Major Inducement Grant to Key New Hire - Stock Titan

Oct 01, 2025

Sep 30, 2025